OA12819A - Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. - Google Patents

Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. Download PDF

Info

Publication number: OA12819A
Authority: OA; OAPI
Prior art keywords: docetaxel; doxorubicin; cyclophosphamide; cancer; dose
Prior art date: 2002-05-17

Application number

OA1200400307A

Other languages

English (en)

Inventor

Hichem Chakroun

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2003-05-15

Publication date

2006-07-10

2003-05-15 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2006-07-10 Publication of OA12819A publication Critical patent/OA12819A/en

Links

AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title claims abstract description 56
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 40
229960003668 docetaxel Drugs 0.000 title claims abstract description 33
229960004679 doxorubicin Drugs 0.000 title claims abstract description 27
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title claims abstract description 21
238000009098 adjuvant therapy Methods 0.000 title claims abstract description 21
229960004397 cyclophosphamide Drugs 0.000 title claims abstract description 21
206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 7
206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 7
206010006187 Breast cancer Diseases 0.000 title claims description 8
208000026310 Breast neoplasm Diseases 0.000 title claims description 6
210000000481 breast Anatomy 0.000 title description 6
238000000034 method Methods 0.000 claims abstract description 12
206010055113 Breast cancer metastatic Diseases 0.000 claims abstract description 9
230000001225 therapeutic effect Effects 0.000 claims abstract description 4
206010028980 Neoplasm Diseases 0.000 claims description 30
201000011510 cancer Diseases 0.000 claims description 11
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
239000002671 adjuvant Substances 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
238000011282 treatment Methods 0.000 abstract description 8
230000004083 survival effect Effects 0.000 description 13
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
229940063683 taxotere Drugs 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
229960002949 fluorouracil Drugs 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000003054 hormonal effect Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000009093 first-line therapy Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
UPAWIKUZXZKSOH-OPSIUPSMSA-N 2-(dimethylamino)ethyl 4-(butylamino)benzoate;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;methyl (1s,3s,4r,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1.O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 UPAWIKUZXZKSOH-OPSIUPSMSA-N 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
238000002224 dissection Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004217 heart function Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
238000009101 premedication Methods 0.000 description 1
238000009094 second-line therapy Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA1200400307A 2002-05-17 2003-05-15 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. OA12819A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38085002P	2002-05-17	2002-05-17

Publications (1)

Publication Number	Publication Date
OA12819A true OA12819A (en)	2006-07-10

Family

ID=29550025

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400307A OA12819A (en)	2002-05-17	2003-05-15	Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer.

Country Status (28)

Country	Link
US (2)	US20040014694A1 (es)
EP (1)	EP1507573A1 (es)
JP (1)	JP4773719B2 (es)
KR (1)	KR20050000544A (es)
CN (1)	CN1652845A (es)
AU (1)	AU2003244646B2 (es)
BR (1)	BR0310026A (es)
CA (1)	CA2486124A1 (es)
CR (1)	CR7575A (es)
EC (1)	ECSP045433A (es)
HR (1)	HRPK20041072B3 (es)
IL (1)	IL165214A0 (es)
MA (1)	MA27417A1 (es)
ME (2)	MEP16308A (es)
MX (1)	MXPA04010640A (es)
MY (1)	MY146533A (es)
NO (1)	NO20045370L (es)
NZ (1)	NZ535992A (es)
OA (1)	OA12819A (es)
PA (1)	PA8574001A1 (es)
RS (1)	RS96304A (es)
RU (1)	RU2321396C2 (es)
TN (1)	TNSN04217A1 (es)
TW (1)	TWI374741B (es)
UA (1)	UA81628C2 (es)
UY (1)	UY27812A1 (es)
WO (1)	WO2003097164A1 (es)
ZA (1)	ZA200408549B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2263694B1 (en) *	2003-09-25	2013-06-12	Astellas Pharma Inc.	Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
RU2265440C2 (ru) *	2004-01-13	2005-12-10	Ростовский научно-исследовательский онкологический институт МЗ РФ	Способ предоперационного лечения рака молочной железы
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7776832B2 (en) *	2006-04-21	2010-08-17	Gem Pharmaceuticals, Llc	Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
US20080085879A1 (en) *	2006-08-31	2008-04-10	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
BR112013025410A2 (pt) *	2011-04-01	2016-12-20	Astrazeneca Ab	tratamento terapêutico
MY194408A (en)	2011-10-14	2022-11-30	Genentech Inc	Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
CA2856646C (en)	2011-11-30	2020-01-14	Astrazeneca Ab	Combination treatment of cancer
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
US20160067182A1 (en) *	2013-04-09	2016-03-10	Merrimack Pharmaceuticals, Inc.	Methods and compositions for improving outcomes of liposomal chemotherapy
RU2020120593A (ru)	2014-04-25	2020-09-01	Дженентек, Инк.	Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
WO2016005962A2 (en)	2014-07-11	2016-01-14	Dr. Reddy’S Laboratories Limited	Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en)	2014-07-11	2020-12-01	Dr. Reddys Laboratories Limited	Stable liquid formulations of cyclophosphamide and its impurities
HK1249052A1 (zh)	2015-03-06	2018-10-26	BeyondSpring Pharmaceuticals Inc.	治疗与ras突变相关的癌症的方法
MX376122B (es)	2015-07-13	2025-03-07	Beyondspring Pharmaceuticals Inc	Composiciones de plinabulina.
WO2017068227A1 (es) *	2015-10-22	2017-04-27	Universidade De Santiago De Compostela	Métodos para utilizar reguladores de aumento de la expresión o activación de p53 y/o reguladores de disminución o inhibidores de la expresión de p63-alfa para el tratamiento de nafld (enfermedad de hígado graso no-alcohólico) y/o nash (esteatohepatitis no- alcohólica)
SG11201806583XA (en)	2016-02-08	2018-09-27	Beyondspring Pharmaceuticals Inc	Compositions containing tucaresol or its analogs
BR112018074990A2 (pt)	2016-06-06	2019-03-12	Beyondspring Pharmaceuticals, Inc.	composição, usos e método para reduzir neutropenia
WO2018039452A1 (en) *	2016-08-24	2018-03-01	The Wistar Institute Of Anatomy And Biology	Methods of treating cancers with chemotherapy with reduced toxicity
US11491147B2 (en) *	2016-10-03	2022-11-08	Indiana University Research And Technology Corporation	Combination drug therapy reduces PARP-1 related DNA repair and increases the efficacy of genotoxic agents
US11633393B2 (en)	2017-01-06	2023-04-25	Beyondspring Pharmaceuticals, Inc.	Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) *	2017-02-01	2020-11-25	Beyondspring Pharmaceuticals, Inc.	NEUTROPENIA REDUCTION METHOD
CN116531511A (zh)	2017-03-02	2023-08-04	豪夫迈·罗氏有限公司	Her2阳性乳腺癌的辅助治疗
KR20200112881A (ko)	2018-01-24	2020-10-05	비욘드스프링 파마수티컬스, 인코포레이티드.	플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
AU2019288813B2 (en) *	2018-06-22	2023-06-29	Hendrix College	Methods and compositions for inhibition of dihydroorotate dehydrogenase
EP4319751A4 (en)	2021-04-09	2025-02-26	Beyondspring Pharmaceuticals, Inc.	THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN115969792A (zh) *	2023-01-29	2023-04-18	常州金远药业制造有限公司	一种紫杉烷类药物与环磷酰胺共载载药脂质体制备方法
CN116870019A (zh) *	2023-02-03	2023-10-13	大连理工大学	一种具有协同增效作用的药物组合物及其在癌症化疗中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) *	1993-11-08	2002-08-27	Aventis Pharma S.A.	Antitumor compositions containing taxane derivatives
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) *	1996-02-01	2001-07-17	Sloan-Kettering Institute Of Cancer Research	Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) *	1996-07-17	2001-11-27	Sloan-Kettering Institute For Cancer Research	Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) *	1999-09-13	2003-04-01	Nobex Corporation	Taxane prodrugs
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) *	2000-12-01	2002-09-12	Wen-Jen Hwu	Compositions and methods for the treatment of cancer

2003
- 2003-05-15 RU RU2004136984/15A patent/RU2321396C2/ru not_active IP Right Cessation
- 2003-05-15 RS YU96304A patent/RS96304A/sr unknown
- 2003-05-15 UA UA20041210381A patent/UA81628C2/uk unknown
- 2003-05-15 CN CNA038112388A patent/CN1652845A/zh active Pending
- 2003-05-15 JP JP2004505157A patent/JP4773719B2/ja not_active Expired - Fee Related
- 2003-05-15 AU AU2003244646A patent/AU2003244646B2/en not_active Ceased
- 2003-05-15 ME MEP-163/08A patent/MEP16308A/xx unknown
- 2003-05-15 ME MEP-2008-163A patent/ME00055B/me unknown
- 2003-05-15 NZ NZ535992A patent/NZ535992A/en not_active IP Right Cessation
- 2003-05-15 WO PCT/EP2003/007443 patent/WO2003097164A1/en not_active Ceased
- 2003-05-15 CA CA002486124A patent/CA2486124A1/en not_active Abandoned
- 2003-05-15 EP EP03738122A patent/EP1507573A1/en not_active Withdrawn
- 2003-05-15 MX MXPA04010640A patent/MXPA04010640A/es active IP Right Grant
- 2003-05-15 IL IL16521403A patent/IL165214A0/xx unknown
- 2003-05-15 BR BR0310026-0A patent/BR0310026A/pt not_active IP Right Cessation
- 2003-05-15 KR KR10-2004-7018431A patent/KR20050000544A/ko not_active Withdrawn
- 2003-05-15 HR HR20041072A patent/HRPK20041072B3/xx not_active IP Right Cessation
- 2003-05-15 OA OA1200400307A patent/OA12819A/en unknown
- 2003-05-16 MY MYPI20031829A patent/MY146533A/en unknown
- 2003-05-16 PA PA20038574001A patent/PA8574001A1/es unknown
- 2003-05-16 UY UY27812A patent/UY27812A1/es not_active Application Discontinuation
- 2003-05-16 US US10/439,827 patent/US20040014694A1/en not_active Abandoned
- 2003-05-16 TW TW092113275A patent/TWI374741B/zh not_active IP Right Cessation
2004
- 2004-10-21 ZA ZA2004/08549A patent/ZA200408549B/en unknown
- 2004-11-03 MA MA27924A patent/MA27417A1/fr unknown
- 2004-11-11 TN TNP2004000217A patent/TNSN04217A1/en unknown
- 2004-11-16 EC EC2004005433A patent/ECSP045433A/es unknown
- 2004-11-17 CR CR7575A patent/CR7575A/es unknown
- 2004-12-08 NO NO20045370A patent/NO20045370L/no not_active Application Discontinuation
2007
- 2007-06-28 US US11/769,859 patent/US20070265213A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TWI374741B (en)	2012-10-21
RU2321396C2 (ru)	2008-04-10
IL165214A0 (en)	2005-12-18
RU2004136984A (ru)	2005-06-27
TNSN04217A1 (en)	2007-03-12
BR0310026A (pt)	2005-02-15
UA81628C2 (uk)	2008-01-25
HRPK20041072B3 (hr)	2007-07-31
HRP20041072A2 (en)	2005-06-30
US20040014694A1 (en)	2004-01-22
TW200407152A (en)	2004-05-16
AU2003244646B2 (en)	2008-08-07
RS96304A (sr)	2006-10-27
CN1652845A (zh)	2005-08-10
MA27417A1 (fr)	2005-07-01
MXPA04010640A (es)	2005-08-16
ME00055B (me)	2010-10-10
AU2003244646A1 (en)	2003-12-02
MY146533A (en)	2012-08-15
ECSP045433A (es)	2005-01-03
NZ535992A (en)	2008-11-28
CA2486124A1 (en)	2003-11-27
ZA200408549B (en)	2006-01-25
JP2005529925A (ja)	2005-10-06
CR7575A (es)	2006-05-10
NO20045370L (no)	2004-12-08
PA8574001A1 (es)	2003-12-19
US20070265213A1 (en)	2007-11-15
WO2003097164A1 (en)	2003-11-27
UY27812A1 (es)	2003-11-28
MEP16308A (en)	2010-06-10
EP1507573A1 (en)	2005-02-23
KR20050000544A (ko)	2005-01-05
JP4773719B2 (ja)	2011-09-14

Publication	Publication Date	Title
OA12819A (en)	2006-07-10	Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer.
RU2587013C2 (ru)	2016-06-10	Комбинированная химиотерапия
CN1703223A (zh)	2005-11-30	喹唑啉衍生物 z d 6 4 7 4组合吉西他滨并任选组合电离辐射在治疗与血管生成和 /或血管通透性增加相关的疾病中的用途
JP2002504511A5 (es)	2010-08-19
JP2009536956A (ja)	2009-10-22	抗癌治療法
JP2007511509A (ja)	2007-05-10	Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
Baghi et al.	2006	A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)
EP1206256B1 (en)	2005-05-04	Combination therapy using pentafluorobenzenesulfonamide and platin compound
US20050288378A1 (en)	2005-12-29	Cancer chemotherapy
CN102526024B (zh)	2015-07-22	一种抗癌药物组合物
RU2284818C2 (ru)	2006-10-10	Комбинированная химиотерапия
CN111773388B (zh)	2023-07-18	A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
US20080318880A1 (en)	2008-12-25	Neoadjuvant treatment of Breast Cancer
US20020013362A1 (en)	2002-01-31	Paclitaxel treatment regimen for metastatic melanoma
KR20060036058A (ko)	2006-04-27	결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
ZA200508696B (en)	2006-07-26	Use of irinotecan for treatment of resistant breast cancer
JP2006516533A (ja)	2006-07-06	アントラサイクリンおよびタキサンによる転移性乳癌の治療
KR20010102402A (ko)	2001-11-15	상승작용성 항종양 조성물
EP1733046A1 (en)	2006-12-20	Combination therapies with epothilones and carboplatin
JP2007523825A (ja)	2007-08-23	乳癌治療のためのｄｐｐｅと他の化学療法剤との併用
ZA200607806B (en)	2008-06-25	Combination therapies with epothilones and carboplatin
MXPA06010921A (es)	2007-04-20	Terapias de combinacion con epotilonas y carboplatin